公司資料
Jaguar Health 股價、新聞與催化劑
- 股票代碼:
- JAGX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.75 USD (-21.28%)
收盤價
最後更新: 2026年9月17日
2.12M USD
市值
股價為何變動
截至 2026年9月17日，JAGX 下跌 21.3%，收於 $2.75。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
Jaguar Health is a biopharmaceutical company focused on gastrointestinal and rare-disease therapies, with Mytesi as a key commercial asset. Its story combines niche commercialization with a pipeline aimed at high-unmet-need GI indications.
所在地與產業分類
Jaguar Health is headquartered in the United States and listed on NASDAQ. It sits in specialty biopharma with a GI and rare-disease profile.
商業模式特徵
The business depends on product sales, label or indication expansion, and the ability to keep a narrow franchise financed. Investors usually watch commercial traction, regulatory progress, and pipeline updates.
生技產業定位
Jaguar occupies a niche GI-specialty position within biotech. Its stock tends to move on commercial execution and the market's view of whether the portfolio can expand beyond a single product.
未來催化劑
- The next few months for Jaguar Health are centered on its latest development priorities. The latest company update points to commercial rights for Mytesi ® and Canalevia ® -CA1 Company continues its focus on crofelemer development efforts for rare-disease intestinal failure indications. If that progress holds, the program should stay on the radar through the rest of the quarter. The partnership angle also matters here, especially around Q4 2025, buoyed by license of U.S.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。